Tetra Bio-Pharma Inc. has received clearance from Health Canada to proceed with a first-in-human trial in Canada using oral ARDS-003 (onternabez) to treat various immunomodulatory conditions. Oral ARDS-003 is positioned to modulate acute systemic inflammation and prevent sepsis, acute respiratory distress syndrome (ARDS) and organ damage.
Researchers from Wenzhou Medical University and affiliated organizations presented the discovery of novel anti-inflammatory agents. Synthesis and optimization of a series of 4-oxo-N-phenyl-1,4-dihydroquinoline-3-carboxamide derivatives led to the identification of compound [I] as the lead, as it exhibited the best inhibitory effect in vitro. More specifically, [I] demonstrated the strongest inhibitory effect on LPS-induced TNF-α (82.58%) and IL-6 (75.05%) expression, while exhibiting no cytotoxicity at 10 μM in J774A.1 macrophages.
Previa Medical SA will begin clinical trials later this year of its artificial intelligence software designed for early detection of sepsis after it raised €2.1 million (US $2.2 million) in seed funds.
Cathepsin L (CTS-L) is a lysosomal enzyme responsible for degrading endocytosed proteins to generate immunogenic antigens for adaptive immunities. In the current study, researchers reported data from a study that aimed to assess the potential of targeting procathepsin L (pCTS-L) as a potential therapeutic strategy against sepsis.
Cytovale Inc. received U.S. FDA 510(k) clearance for its Intellisep sepsis test, which can aid in the diagnosis of the often fatal condition within 10 minutes. Cytovale is one of several companies and collaborations that aim to sharply reduce the time to diagnosis and the mortality rate for sepsis by providing quicker, more informative test results and standardizing protocols.
The U.S. FDA has granted Opticyte Inc. a breakthrough device designation for its Cell O2 patient monitor, a noninvasive technology for monitoring patients at risk of organ failure. The device could help to reduce serious illness and deaths by alerting clinicians to patients experiencing organ failure before irreversible damage occurs.
Qrons Inc. has established a collaboration with scientists at a public research university in Israel, by which Tellurium-based compounds in combination with Qrons' QS-200 product candidate and other configurations will be explored as treatment for diffused axonal injuries (concussions), which accounts for approximately 89% of traumatic brain injuries (TBIs).
Tetra Bio-Pharma Inc. has reported results from a study of ARDS-003 (onternabez) combined with favipiravir against acute respiratory distress syndrome (ARDS), sepsis and COVID-19 through PREPAiRE, an artificial intelligence (AI)-powered platform which integrates target identification, validation, lead discovery optimization, drug synthesis and preclinical testing.
Brain-derived neurotrophic factor (BDNF) is a pleiotropic cytokine that has been shown to be involved in metabolic regulation, development of lung disease and support of hematopoiesis, apart from its known roles in the central nervous system. Its plasma levels during sepsis were investigated in this study.
Deepull Diagnostics SL has raised €13 million (US$12.71 million) in a series B round to advance development of a PCR-based rapid diagnostic for the early diagnosis of sepsis and acute infections.
